BR112022014667A2 - Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos - Google Patents
Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmosInfo
- Publication number
- BR112022014667A2 BR112022014667A2 BR112022014667A BR112022014667A BR112022014667A2 BR 112022014667 A2 BR112022014667 A2 BR 112022014667A2 BR 112022014667 A BR112022014667 A BR 112022014667A BR 112022014667 A BR112022014667 A BR 112022014667A BR 112022014667 A2 BR112022014667 A2 BR 112022014667A2
- Authority
- BR
- Brazil
- Prior art keywords
- multivalent
- single domain
- domain antibodies
- polypeptides
- constructs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967533P | 2020-01-29 | 2020-01-29 | |
| PCT/US2021/015590 WO2021155071A1 (en) | 2020-01-29 | 2021-01-28 | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014667A2 true BR112022014667A2 (pt) | 2022-09-20 |
Family
ID=74673405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014667A BR112022014667A2 (pt) | 2020-01-29 | 2021-01-28 | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12522661B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4097129A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7789002B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220148175A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115380047A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021213177A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022014667A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3168832A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294879A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009306A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021155071A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| TW202010757A (zh) | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| US12590169B2 (en) | 2018-10-11 | 2026-03-31 | Inhibrx Biosciences, Inc. | 5T4 single domain antibodies and therapeutic compositions thereof |
| JP7611820B2 (ja) | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Dll3シングルドメイン抗体およびその治療用組成物 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| CN116635425A (zh) * | 2020-11-03 | 2023-08-22 | 德国癌症研究中心公共法律基金会 | 靶细胞限制性、共刺激性、双特异性二价抗cd28抗体 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN114605540B (zh) * | 2021-08-26 | 2024-06-21 | 北京大学深圳研究生院 | 一种抗cd28纳米抗体、编码基因及应用 |
| EP4399229A2 (en) * | 2021-09-06 | 2024-07-17 | Biond Biologics Ltd. | Cd28 shedding blocking agents |
| US20240400633A1 (en) * | 2021-09-30 | 2024-12-05 | Orionis Biosciences, Inc. | Split human ifn-gamma and tnf-alpha constructs and uses thereof |
| WO2023064876A1 (en) * | 2021-10-14 | 2023-04-20 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| MX2024003887A (es) | 2021-10-14 | 2024-07-09 | Arsenal Biosciences Inc | Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica. |
| IL314993A (en) | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| EP4490192A1 (en) | 2022-03-07 | 2025-01-15 | Novimmune S.A. | Cd28 bispecific antibodies for targeted t cell activation |
| WO2023174925A1 (en) | 2022-03-14 | 2023-09-21 | Novimmune Sa | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| WO2023193239A1 (en) * | 2022-04-08 | 2023-10-12 | Peter Peizhi Luo | Anti-cd28 antibodies and methods of use thereof |
| US20230383012A1 (en) * | 2022-04-13 | 2023-11-30 | Xencor, Inc. | Antibodies that bind pd-l1, pd-l2, and/or cd28 |
| EP4519326A4 (en) * | 2022-05-04 | 2026-05-06 | Janux Therapeutics Inc | TUMOR-ACTIVATED MULTISPECIFIC ANTIBODIES TO TARGET CD28 AND PD-L1 AND THEIR METHODS OF USE |
| EP4558519A1 (en) * | 2022-07-22 | 2025-05-28 | Philogen S.p.A. | Anti-cd28 antibodies |
| CN117467009A (zh) * | 2022-07-28 | 2024-01-30 | 四川思柏沃生物技术有限公司 | 抗cd28人源化单域抗体 |
| WO2024024882A1 (en) * | 2022-07-28 | 2024-02-01 | Chugai Seiyaku Kabushiki Kaisha | Molecule specifically acting in a tissue where a cell death being observed |
| EP4565610A1 (en) * | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| TW202430561A (zh) * | 2022-09-30 | 2024-08-01 | 法商賽諾菲公司 | 抗cd28抗體 |
| AU2023356326A1 (en) | 2022-10-06 | 2025-03-27 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| AU2023362569A1 (en) | 2022-10-21 | 2025-04-24 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
| WO2024237744A1 (ko) * | 2023-05-18 | 2024-11-21 | 서울대학교산학협력단 | 항-cd40l/항-cd28 이중 특이 항체 및 이의 용도 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| TW202544034A (zh) * | 2024-05-06 | 2025-11-16 | 美商榮都醫療公司 | 結合至cd28及nectin-4之雙特異性抗體 |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| EP1002861A1 (en) | 1998-10-26 | 2000-05-24 | Unilever Plc | Antigen-binding proteins comprising a linker which confers restricted conformational flexibility |
| CN1294148C (zh) * | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DK1678314T3 (da) | 2003-10-22 | 2012-12-03 | Keck Graduate Inst | Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi |
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| CN100376599C (zh) * | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| SG170091A1 (en) | 2006-03-10 | 2011-04-29 | Wyeth Corp | Anti-5t4 antibodies and uses thereof |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| AU2008329518A1 (en) | 2007-11-27 | 2009-06-04 | Viventia Biotechnologies Inc. | Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US8557965B2 (en) | 2008-04-07 | 2013-10-15 | Ablynx N.V. | Single variable domains against notch pathway members |
| MX2011000501A (es) * | 2008-07-18 | 2011-05-23 | Squibb Bristol Myers Co | Composiciones monovalentes para union a cd28 y metodos de uso. |
| AR073459A1 (es) * | 2008-07-18 | 2010-11-10 | Domantis Ltd | Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso |
| US20110097339A1 (en) | 2008-07-18 | 2011-04-28 | Domantis Limited | Compositions monovalent for CD28 binding and methods of use |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| CN102361884A (zh) | 2009-04-07 | 2012-02-22 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-2/抗-c-Met抗体 |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| WO2012162067A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| MX2014003313A (es) | 2011-09-23 | 2014-07-09 | Amgen Res Munich Gmbh | Moleculas de union biespecificas para 5t4 y cd3. |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| KR101814370B1 (ko) | 2011-12-27 | 2018-01-12 | 재단법인 생물기술개발중심 | 경쇄-가교된 이중특이성 항체 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| BR112015000798A2 (pt) | 2012-07-13 | 2017-06-27 | Zymeworks Inc | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 |
| CN104640561A (zh) | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| US20150239991A1 (en) | 2012-09-25 | 2015-08-27 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| CA2889951C (en) | 2012-11-02 | 2023-04-18 | Zymeworks Inc. | Crystal structures of heterodimeric fc domains |
| EA032681B1 (ru) | 2012-11-27 | 2019-07-31 | Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн | ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ |
| US9703815B2 (en) | 2012-12-17 | 2017-07-11 | Salesforce.Com, Inc. | Third party files in an on-demand database service |
| KR20150095684A (ko) | 2012-12-18 | 2015-08-21 | 노파르티스 아게 | 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법 |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| EP3587448B1 (en) | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| KR102813816B1 (ko) | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| JP6693872B2 (ja) | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス,インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| PL3177643T3 (pl) | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T |
| EP2982693A1 (en) | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| KR102485788B1 (ko) | 2014-08-27 | 2023-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 항체, 조성물 및 용도 |
| WO2016034666A1 (en) | 2014-09-04 | 2016-03-10 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| EP3197916A2 (en) | 2014-09-25 | 2017-08-02 | Amgen Inc. | Protease-activatable bispecific proteins |
| KR20170062505A (ko) * | 2014-09-30 | 2017-06-07 | 브리스톨-마이어스 스큅 컴퍼니 | Cd28에 대해 지시된 도메인 항체를 사용하여 전신성 홍반성 루푸스를 치료하는 방법 |
| JP2017536341A (ja) | 2014-10-09 | 2017-12-07 | エンクマフ アーゲー | 卵巣がんの処置における使用のためのCD3εおよびROR1に対する二特異性抗体 |
| JP6696982B2 (ja) | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3および腫瘍抗原に結合するヘテロ二量体抗体 |
| WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| ES2935274T3 (es) | 2014-12-05 | 2023-03-03 | Merck Patent Gmbh | Anticuerpo con intercambio de dominios |
| MX384198B (es) | 2014-12-19 | 2025-03-14 | Chiome Bioscience Inc | Proteina de fusion que comprende tres dominios de union a 5t4 y cd3. |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| CA3081058C (en) | 2015-01-16 | 2024-02-20 | Academia Sinica | Linker units and their uses in configuring pharmaceutical molecules |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| EP3247407A4 (en) | 2015-01-21 | 2018-08-22 | Inhibrx LP | Non-immunogenic single domain antibodies |
| MA41613A (fr) | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| ES2984656T3 (es) | 2015-05-13 | 2024-10-30 | Ablynx Nv | Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3 |
| WO2016192613A1 (zh) | 2015-06-01 | 2016-12-08 | 中山大学 | 具有融合至常规Fab片段的单域抗原结合片段的二价抗体 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| JP2018523686A (ja) | 2015-08-17 | 2018-08-23 | マクロジェニクス,インコーポレーテッド | B7‐h3及びcd3に結合できる二重特異性1価ダイアボディ並びにその使用 |
| MY206406A (en) | 2015-10-02 | 2024-12-16 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| PE20181349A1 (es) | 2015-10-07 | 2018-08-22 | Hoffmann La Roche | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador |
| GB201602156D0 (en) | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
| US20190112380A1 (en) | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| ES3056995T3 (en) | 2016-04-13 | 2026-02-25 | Vivia Biotech Sl | Ex vivo bite-activated t cells |
| BR112018071612A2 (pt) | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| WO2018027025A1 (en) | 2016-08-03 | 2018-02-08 | Oncomed Pharmaceuticals, Inc. | Cd40-binding agents and uses thereof |
| CN108084265B (zh) | 2016-11-23 | 2021-07-02 | 复旦大学 | 特异性结合人的5t4抗原的全人源单域抗体及其应用 |
| CA3047070A1 (en) | 2017-01-03 | 2018-07-12 | F.Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| EP3595705A1 (en) | 2017-03-15 | 2020-01-22 | Oxford BioMedica (UK) Limited | Method |
| CN110402255B (zh) | 2017-04-04 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 新颖的能够特异性结合cd40和fap的双特异性抗原结合分子 |
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
| TW202010757A (zh) | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| WO2019201866A1 (en) * | 2018-04-16 | 2019-10-24 | Swedish Orphan Biovitrum Ab (Publ) | Fusion protein |
| WO2020023553A1 (en) * | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| CN113166261A (zh) | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
| AU2019356573B2 (en) | 2018-10-11 | 2025-12-18 | Inhibrx Biosciences, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
| US12590169B2 (en) | 2018-10-11 | 2026-03-31 | Inhibrx Biosciences, Inc. | 5T4 single domain antibodies and therapeutic compositions thereof |
| JP7611820B2 (ja) * | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Dll3シングルドメイン抗体およびその治療用組成物 |
-
2021
- 2021-01-28 EP EP21707540.7A patent/EP4097129A1/en active Pending
- 2021-01-28 CA CA3168832A patent/CA3168832A1/en active Pending
- 2021-01-28 CN CN202180023573.4A patent/CN115380047A/zh active Pending
- 2021-01-28 WO PCT/US2021/015590 patent/WO2021155071A1/en not_active Ceased
- 2021-01-28 US US17/795,500 patent/US12522661B2/en active Active
- 2021-01-28 IL IL294879A patent/IL294879A/en unknown
- 2021-01-28 MX MX2022009306A patent/MX2022009306A/es unknown
- 2021-01-28 BR BR112022014667A patent/BR112022014667A2/pt not_active IP Right Cessation
- 2021-01-28 JP JP2022545975A patent/JP7789002B2/ja active Active
- 2021-01-28 KR KR1020227029333A patent/KR20220148175A/ko not_active Ceased
- 2021-01-28 AU AU2021213177A patent/AU2021213177A1/en not_active Abandoned
-
2025
- 2025-12-08 JP JP2025238239A patent/JP2026041922A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021213177A1 (en) | 2022-08-18 |
| CA3168832A1 (en) | 2021-08-05 |
| JP2026041922A (ja) | 2026-03-10 |
| KR20220148175A (ko) | 2022-11-04 |
| CN115380047A (zh) | 2022-11-22 |
| IL294879A (en) | 2022-09-01 |
| MX2022009306A (es) | 2022-09-26 |
| US12522661B2 (en) | 2026-01-13 |
| EP4097129A1 (en) | 2022-12-07 |
| US20230348600A1 (en) | 2023-11-02 |
| JP2023513003A (ja) | 2023-03-30 |
| JP7789002B2 (ja) | 2025-12-19 |
| WO2021155071A1 (en) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009306A (es) | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. | |
| BR112022013236A2 (pt) | Anticorpos anti-cd73 e usos dos mesmos | |
| CL2024003715A1 (es) | Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso. | |
| CY1123609T1 (el) | Βελτιστοποιηση αντισωματων που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (lag-3), και χρησεις εξ΄ αυτων | |
| SA520411173B1 (ar) | Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137 | |
| ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| BR112019010265A2 (pt) | anticorpos anti_cd137 inovadores e usos dos mesmos | |
| BR112021024553A2 (pt) | Molécula de ligação específica para cd73 e uso de molécula de ligação | |
| EA202092735A1 (ru) | Антагонизирующее cd73 антитело | |
| BR112017010110A2 (pt) | anticorpos contra cd73 e usos do mesmo | |
| EP4389226A3 (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| BR112018006547A2 (pt) | anticorpos de pd-1 e usos dos mesmos | |
| BR112016013347A8 (pt) | anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos. | |
| BR112016016207A2 (pt) | Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos | |
| BR112017005110A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. | |
| BR112019000770A2 (pt) | proteínas de ligação semelhantes a anticorpos biespecíficos que se ligam especificamente às cd3 e cd123 | |
| MX2018013548A (es) | Proteinas de union biespecificas y usos de las mismas. | |
| NO20083053L (no) | Humane monoklonale antistoffer mot O8E | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| BR112022022353A2 (pt) | Composições e métodos para reprogramação de tcr usando proteínas de fusão específicas de cd70 | |
| BR112021026309A2 (pt) | Anticorpos para ativação de células t | |
| BR112023000826A2 (pt) | Anticorpo anti-ctla-4 e uso do mesmo | |
| MX2024014591A (es) | Anticuerpo anti-bdca2 y uso del mismo | |
| BR112023022319A2 (pt) | Anticorpos anti-tigit, anticorpos anti-cd96 e métodos de uso dos mesmos | |
| BR112022015656A2 (pt) | Moléculas de ligação ao cd137, molécula de ligação ao pd-l1, composição farmacêutica, e ácido nucleico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: INHIBRX BIOSCIENCES, INC. (US) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2864 DE 25-11-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |